globalagliatin (SY-004) / Yabao Pharma, Eli Lilly - LARVOL DELTA

Unveiling the Influence of a High-Fat Meal on the Pharmacokinetics of Oral Globalagliatin, A Glucokinase Activator, in Healthy Chinese Volunteers. (PubMed, Drugs R D) - "A high-fat meal increased the C, AUC, and AUC of globalagliatin compared with fasting conditions in healthy Chinese adult volunteers. Meanwhile, globalagliatin showed favorable safety and tolerability under fasting or high-fat meal conditions."

Journal • PK/PD data • Hypoglycemia

The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P2 | N=200 | Completed | Sponsor: Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Food-drug Interaction Study of SY-004 in Healthy Subjects (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Not yet recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Drug Interaction Study of SY-004 Capsules in Healthy Subjects (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Not yet recruiting ➔ Completed | Trial completion date: Dec 2021 ➔ Aug 2021 | Trial primary completion date: Nov 2021 ➔ Aug 2021

Trial completion • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of SY-004, a Glucokinase Activator, in Healthy Chinese Adults: A Randomized, Phase Ia, Single-Ascending Dose Study. (PubMed, Clin Ther) - P1 | "SY-004, a new potential glucokinase activator, had favorable safety profiles and good PK characteristics. The glucose-lowering effects were slightly dose related. The SY-004 data in healthy Chinese adults supports further development. ClinicalTrials.gov identifier: NCT03171623."

Journal • PK/PD data

A Food-drug Interaction Study of SY-004 in Healthy Subjects (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Clinical • New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Drug Interaction Study of SY-004 Capsules in Healthy Subjects (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Clinical • New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P2; N=200; Recruiting; Sponsor: Suzhou Yabao Pharmaceutical R&D Co., Ltd.; Trial primary completion date: Jun 2020 ➔ Jun 2021

Clinical • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus